Menlo Therapeutics’ cough drug fails to meet primary endpoint in phase II trial

pharmafile | October 9, 2018 | News story | Manufacturing and Production Phase II, cough, menlo therapeutics, serlopitant 

The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet its primary endpoint in patients with refractory chronic cough in Phase II trials.

The drug also failed to hit primary and secondary efficacy goals in a Phase II trial studying its use in treating pruritis in adults and adolescents with a history of atopic dermatitis earlier this year.

CEO Steve Basta commented “we do not anticipate further development of serlopitant for the treatment of refractory chronic cough” but added that “we are continuing the clinical development of serlopitant for pruritus associated with various conditions given the two successful Phase II clinical trials in which serlopitant demonstrated a reduction in chronic pruritus and pruritus associated with prurigo nodularis”

The Phase II trial involving 185 patients found that those receiving serlopitant had experienced a 31% less reduction in coughing than those taking a placebo. In a secondary analysis 44% of those taking serlopitant and 54% of those taking a placebo experienced a 30% or greater reduction in coughing after 12 weeks of treatment.

Louis Goss

Related Content


Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical …


Retrophin announces positive Phase II results, Shkreli claims credit

Retrophin has announced positive top-line results for trial drug sparsentan in Phase II to treat …

13 deaths in Aurinia’s lupus drug trial despite hitting Phase II target

Canadian biotech Aurinia Pharmaceuticals has announced the topline Phase IIb trial results of its lupus …

Latest content